AU2006343808B2 - Inhibitors of VEGF receptor and HGF receptor signaling - Google Patents

Inhibitors of VEGF receptor and HGF receptor signaling Download PDF

Info

Publication number
AU2006343808B2
AU2006343808B2 AU2006343808A AU2006343808A AU2006343808B2 AU 2006343808 B2 AU2006343808 B2 AU 2006343808B2 AU 2006343808 A AU2006343808 A AU 2006343808A AU 2006343808 A AU2006343808 A AU 2006343808A AU 2006343808 B2 AU2006343808 B2 AU 2006343808B2
Authority
AU
Australia
Prior art keywords
group
alkyl
optionally substituted
yloxy
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006343808A
Other languages
English (en)
Other versions
AU2006343808A1 (en
Inventor
Naomy Bernstein
Stephen William Claridge
Robert Deziel
Federic Gaudette
Marie Claude Granger
Ljubomir Isakovic
Michael Mannion
Franck Raeppel
Stephane Raeppel
Oscar Mario Saavedra
Arkadii Vaisburg
Amal Wahhab
Lijie Zhan
Nancy Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of AU2006343808A1 publication Critical patent/AU2006343808A1/en
Assigned to METHYLGENE INC. reassignment METHYLGENE INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: METHYLGENE, INC.
Assigned to METHYLGENE INC. reassignment METHYLGENE INC. Request for Assignment Assignors: METHYLGENE INC.
Application granted granted Critical
Publication of AU2006343808B2 publication Critical patent/AU2006343808B2/en
Assigned to Mirati Therapeutics, Inc. reassignment Mirati Therapeutics, Inc. Request for Assignment Assignors: METHYLGENE INC.
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2006343808A 2005-05-20 2006-05-19 Inhibitors of VEGF receptor and HGF receptor signaling Active AU2006343808B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68303605P 2005-05-20 2005-05-20
US60/683,036 2005-05-20
US75490205P 2005-12-29 2005-12-29
US60/754,902 2005-12-29
US78505406P 2006-03-22 2006-03-22
US60/785,054 2006-03-22
PCT/IB2006/004306 WO2008041053A2 (en) 2005-05-20 2006-05-19 Inhibitors of vegf receptor and hgf receptor signaling

Publications (2)

Publication Number Publication Date
AU2006343808A1 AU2006343808A1 (en) 2008-04-10
AU2006343808B2 true AU2006343808B2 (en) 2012-03-29

Family

ID=39190471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006343808A Active AU2006343808B2 (en) 2005-05-20 2006-05-19 Inhibitors of VEGF receptor and HGF receptor signaling

Country Status (13)

Country Link
US (2) US8093264B2 (https=)
EP (1) EP1957498B1 (https=)
JP (1) JP5148499B2 (https=)
KR (1) KR101378716B1 (https=)
CN (1) CN101796055B (https=)
AU (1) AU2006343808B2 (https=)
BR (1) BRPI0610322B8 (https=)
CA (1) CA2611370C (https=)
ES (1) ES2623221T3 (https=)
IL (1) IL187484A (https=)
MX (1) MX2007014616A (https=)
NZ (1) NZ564283A (https=)
WO (1) WO2008041053A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
KR101257343B1 (ko) * 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
BRPI0708615A2 (pt) * 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
TW200916447A (en) * 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
BRPI0908573A2 (pt) * 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
MX2011001938A (es) 2008-08-26 2011-03-29 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmaceuticas.
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
ES2578990T3 (es) * 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
JP2013516420A (ja) * 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
EP2539343B1 (en) 2010-02-26 2015-12-30 Evotec International GmbH Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33246A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CN101863911A (zh) * 2010-04-13 2010-10-20 艾琪康医药科技（上海）有限公司 一种1-r1-3,4-脱氢-3或4-r6-哌啶的制备方法
US8455484B2 (en) * 2010-04-16 2013-06-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
KR20130091331A (ko) 2010-07-16 2013-08-16 교와 핫꼬 기린 가부시키가이샤 함질소 방향족 복소환 유도체
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
WO2014079545A1 (en) 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Thioether derivatives as protein kinase inhibitors
EA201691831A1 (ru) 2014-04-25 2017-02-28 Пфайзер Инк. Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
CN105348213A (zh) * 2015-09-22 2016-02-24 武汉理工大学 β-氟烷基-β-氨基酸类化合物的制备方法
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
CN110423218A (zh) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 一种苹果酸卡博替尼合成中杂质的制备方法
CN113336768B (zh) * 2020-02-18 2022-08-19 深圳海王医药科技研究院有限公司 一种多靶点酪氨酸激酶抑制剂
CN114957136A (zh) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 一种用作vegfr抑制剂的抗肿瘤化合物及其用途
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法
CN117902987A (zh) * 2024-01-22 2024-04-19 安庆双启医药科技有限公司 一种3-氟-5-碘苯胺的制备方法
WO2025239980A1 (en) * 2024-05-13 2025-11-20 University Of Virginia Patent Foundation Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CA2367866A1 (en) * 1999-03-23 2000-09-28 Astrazeneca Ab Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
CA2502614A1 (en) * 2002-11-25 2004-06-10 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
WO2006004833A2 (en) * 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2006116713A1 (en) * 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1061395A (en) 1993-11-30 1995-06-19 Mcgill University Inhibition of dna methyltransferase
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
EP2093292A2 (en) 2000-03-24 2009-08-26 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP2258366B1 (en) * 2001-06-22 2013-04-03 Kirin Pharma Kabushiki Kaisha Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
JP2006503082A (ja) 2002-10-17 2006-01-26 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP1660504B1 (en) * 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
PT2213661E (pt) * 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
WO2005052872A1 (en) 2003-11-21 2005-06-09 Facil, Llc Financial transaction system and method
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1768984B1 (en) 2004-07-16 2010-10-20 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
US7647492B2 (en) 2004-09-15 2010-01-12 Check Point Software Technologies Inc. Architecture for routing and IPSec integration
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CA2367866A1 (en) * 1999-03-23 2000-09-28 Astrazeneca Ab Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
CA2502614A1 (en) * 2002-11-25 2004-06-10 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
WO2006004833A2 (en) * 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2006116713A1 (en) * 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
IL187484A (en) 2014-04-30
BRPI0610322B1 (pt) 2020-12-01
CN101796055A (zh) 2010-08-04
CN101796055B (zh) 2013-09-04
KR20080059112A (ko) 2008-06-26
EP1957498A4 (en) 2010-10-27
AU2006343808A1 (en) 2008-04-10
US8329726B2 (en) 2012-12-11
IL187484A0 (en) 2011-08-01
WO2008041053A2 (en) 2008-04-10
JP5148499B2 (ja) 2013-02-20
MX2007014616A (es) 2009-08-12
US20120083482A1 (en) 2012-04-05
KR101378716B1 (ko) 2014-04-10
JP2009504804A (ja) 2009-02-05
BRPI0610322A2 (pt) 2010-06-15
EP1957498B1 (en) 2017-02-15
US20070004675A1 (en) 2007-01-04
NZ564283A (en) 2011-07-29
CA2611370C (en) 2014-11-25
EP1957498A2 (en) 2008-08-20
WO2008041053A3 (en) 2009-12-23
US8093264B2 (en) 2012-01-10
CA2611370A1 (en) 2006-11-20
BRPI0610322B8 (pt) 2021-05-25
ES2623221T3 (es) 2017-07-10

Similar Documents

Publication Publication Date Title
AU2006343808B2 (en) Inhibitors of VEGF receptor and HGF receptor signaling
AU2008293038B2 (en) Inhibitors of protein tyrosine kinase activity
CA2608726C (en) Inhibitors of vegf receptor and hgf receptor signaling
AU2010246540B2 (en) Inhibitors of protein tyrosine kinase activity
WO2008046216A1 (en) Kinase inhibitors and uses thereof
HK1125627B (en) Inhibitors of vegf receptor and hgf receptor signaling
HK1125627A (en) Inhibitors of vegf receptor and hgf receptor signaling
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: METHYLGENE INC.

Free format text: FORMER APPLICANT(S): METHYLGENE INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MIRATI THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): METHYLGENE INC.